Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Relmada Therapeutics Inc (RLMD)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.77-9.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RLMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage operating losses and cash burn | The company manages cash burn and operating losses carefully. | Broken | Operating losses worsen beyond -$19.5M in 2026-Q1 | Operating income: $-15.011M FY2026-Q2; GAAP. Published target: Operating losses no worse than -$19.5M in 2026-Q1. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 2026-15,011,027 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is speculative clinical-stage growth, not a proven durable compounder: recent financial performance is weak, earnings quality is fragile, and risk is elevated. The thesis is on watch, with low confidence, despite recent positive Phase 2 data and a substantial cash raise.
The evidence provides no valuation or market-expectations measure, so whether RLMD is cheap or expensive versus peers cannot be assessed. What is clear is that the business is loss-making, and its value case depends heavily on NDV-01 development rather than established earnings.
Near term, results have been uneven, with earnings misses in March and May followed by a beat in August; the next update carries elevated miss risk. Over the multi-year view, management says available cash should fund operations through 2029, while the key execution milestones are the planned IND submission by year-end 2026 and Phase 3 start after clearance.
The central swing factor is whether management delivers the NDV-01 IND and Phase 3 RESCUE program on schedule, with Phase 2 complete-response data providing the stated clinical support. Near term, a guidance cut or continued weakness in jobs data could weigh on the setup, while stronger results and guidance from healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, RLMD's thesis remains a high-risk clinical-development story: funding and Phase 2 data support progress, but weak performance and execution uncertainty keep confidence low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “About NDV-01 NDV-01 is a novel, sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce) being developed for the treatment of non-muscle invasive bladder cancer (NMIBC).” “Upcoming AUA2026 Presentations and NDV-01 Phase 2 Data Highlights: Relmada will present two abstracts at AUA2026 including: (1) NDV-01 Phase 2 data (12-month follow-up), and (2) the Phase 3 RESCUE program design (Clinical Trials in Progress session).”
Advance Phase 2 clinical trials for NDV-01 | Relmada is advancing Phase 2 trials for NDV-01. | Intact | Failure to initiate Phase 2 PWS study or negative 12-month data | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Raise capital through private placement | They raised capital through private placement to fund development. | Intact | Failure to secure needed funding through private placement | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.41 → $-0.80 · observed estimates
$0.00B → $0.03B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.41 | $0 | 1 / 6 |
| 2026-07-25 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-07-26 | $-0.41 | $0 | 1 / 6 |
| 2026-07-27 | $-0.41 | $0 | 1 / 6 |
| 2026-07-28 | $-0.41 | $0 | 1 / 6 |
| 2026-07-29 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-07-30 | $-0.41 | $0 | 1 / 6 |
| 2026-07-31 | $-0.41 | $0 | 1 / 6 |
| 2026-08-01 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-02 | $-0.41 | $0 | 1 / 6 |
| 2026-08-03 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-04 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-05 | $-0.41 | $0 | 1 / 6 |
| 2026-08-06 | $-0.41 | $0 | 1 / 6 |
| 2026-08-08 | $-0.41 | $0 | 1 / 6 |
| 2026-08-09 | $-0.41 | $0 | 1 / 6 |
| 2026-08-10 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-12 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-13 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-14 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-15 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-16 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-17 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-18 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-19 | $-0.96 | $32,450,000 | 3 / 6 |
| 2026-08-20 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-21 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-22 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-23 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-24 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-25 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-26 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-27 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-28 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-29 | $-0.78 | $32,450,000 | 3 / 6 |
| 2026-08-30 | $-0.77 | $32,450,000 | 3 / 6 |
| 2026-08-31 | $-0.77 | $32,450,000 | 3 / 6 |
| 2026-09-01 | $-0.77 | $32,450,000 | 3 / 6 |
| 2026-09-02 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-03 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-04 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-05 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-06 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-07 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-08 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-09 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-10 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-11 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-12 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-13 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-14 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-15 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-16 | $-0.77 | $32,450,000 | 2 / 5 |
| 2026-09-17 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-18 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-19 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-20 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-21 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-22 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-23 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-24 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-25 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-26 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-27 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-28 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-29 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-09-30 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-01 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-02 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-03 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-04 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-05 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-06 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-07 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-08 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-09 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-10 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-11 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-12 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-13 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-14 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-15 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-16 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-17 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-18 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-19 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-20 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-21 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-22 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-23 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-24 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-25 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-26 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-27 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-28 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-29 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-30 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-10-31 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-11-01 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-11-02 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-11-03 | $-0.80 | $32,450,000 | 2 / 4 |
| 2026-11-04 | $-0.80 | $32,450,000 | 2 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.